Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based on a randomized trial that showed a significant improvement in progression-free survival for patients who received VIZIMPRO compared to the standard-of-care treatment. VIZIMPRO, an EGFR inhibitor targeted therapy, is an oral drug that is taken once a day.

The following treatments are approved for first-line treatment of NSCLC with an EGFR mutation: GILOTRIF (afatinib), IRESSA (gefitinib), TAGRISSO (osimertinib), TARCEVA (erlotinib), VIZIMPRO (dacomitinib).

Click here to read the full press release.